This paper introduces CoPPRA, a structural proteomics method to analyze drug combinations in AML, revealing peptide-level accessibility changes linked to conjunctive targeting.

bioRxiv · Sep 28, 2026 · PreprintBiochemistry

Chemical Proteomics of Residual Acute Myeloid Leukemia Cells Reveals Therapeutic Vulnerabilities

Elham Gholizadeh, Uladzislau Vadadokhau, Mücahit Varlı, Danilo Ritz, Komal Kumar Javarappa, Mika Kontro, Blassan Plackal Adimuriyil George, Raphaël Itzykson, Markku T Varjosalo, Risto Renkonen, Esko M Kankuri, Paul A. Haynes, Amir Ata Saei, Mohieddin Jafari

This study uses CoPISA and proteomics to analyze venetoclax-azacitidine response in AML cells, identifying adaptive vulnerabilities like NRP2.

bioRxiv · Sep 23, 2026 · PreprintCancer Biology

DORSSAA: Drug-target interactOmics Resource based on Stability/Solubility Alteration Assay

Ehsan Zangene, Elham Gholizadeh, Veit Schwämmle, Amir Ata Saei, Mathias Wilhelm, Lukas Käll, Mohieddin Jafari

DORSSAA provides a platform for analyzing stability and solubility alteration data to identify drug-protein interactions and therapeutic targets.

Molecular & Cellular Proteomics · Jun 17, 2026Peer-reviewedBioinformatics

Shifting Beyond Classical Drug Synergy in Combinatorial Therapy through Solubility Alterations

Elham Gholizadeh, Ehsan Zangene, Uladzislau Vadadokhau, Danilo Ritz, Juho Jalmari Miettinen, Rabah Soliymani, Marc Baumann, Mathias Wilhelm, Esko M Kankuri, Paul A. Haynes, Caroline Akemi Heckman, Amir Ata Saei, Mohieddin Jafari

This paper introduces CoPISA, a proteomics workflow that identifies combination-specific protein targets in AML, revealing conjunctional targeting mechanisms beyond classical drug synergy.

Nature Communications · Mar 25, 2026Peer-reviewedBiochemistry

CoPISA: Combinatorial Proteome Integral Solubility/Stability Alteration analysis

Ehsan Zangene, Elham Gholizadeh, Uladzislau Vadadokhau, Danilo Ritz, Amir Ata Saei, Mohieddin Jafari

CoPISA provides a proteomics dataset profiling protein solubility and stability responses to single and combined drug treatments in AML cell lines, enabling analysis of combinatorial drug effects.

bioRxiv · Mar 23, 2026 · PreprintBioinformatics

Targeting AML Resistance with Two Novel Combinations Demonstrate Superior Efficacy in TP53, HLA-B, MUC4 and FLT3 mutations

Elham Gholizadeh, Ehsan Zangene, Alun Parsons, Mika Kontro, Caroline Akemi Heckman, Mohieddin Jafari

This study evaluates two drug combinations for AML treatment, showing improved efficacy over venetoclax-based therapy in specific mutation profiles.

Biomedicine & Pharmacotherapy · Oct 13, 2025Peer-reviewedCancer Biology